Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics
Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been...
Main Authors: | Ana Rita Lima, Joana Pinto, Filipa Amaro, Maria de Lourdes Bastos, Márcia Carvalho, Paula Guedes de Pinho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/11/3/181 |
Similar Items
-
Differences in the Volatilomic Urinary Biosignature of Prostate Cancer Patients as a Feasibility Study for the Detection of Potential Biomarkers
by: Giulia Riccio, et al.
Published: (2023-05-01) -
The untargeted urine volatilome for biomedical applications: methodology and volatilome database
by: Maria Llambrich, et al.
Published: (2022-12-01) -
Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis
by: Celia Mallafré-Muro, et al.
Published: (2021-05-01) -
1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia
by: Mohammed Zniber, et al.
Published: (2024-04-01) -
A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer
by: Denise Drago, et al.
Published: (2021-05-01)